Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
AustraliaIPO:
19 April 2012Website:
http://www.immutep.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:57:08 GMTDividend
Analysts recommendations
Institutional Ownership
IMMP Latest News
SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25).
Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will participate in a fireside chat at the Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 9:30 am ET. The fireside chat will be live on M-Vest.
Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of their lead drug, eftilagimod. Despite the disappointing data, IMMP has a strong cash position, giving them a 3-4 year runway to continue their development efforts. The company remains a speculative investment with potential, especially with upcoming results from the AIPAC-003 breast cancer study expected in 2025.
SYDNEY, AUSTRALIA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC).
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces details for an upcoming oral presentation at the European Society for Medical Oncology (ESMO) Virtual Plenary session on July 11, 2024, featuring new clinical data in patients with negative PD-L1 expression (Cohort B) in the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, and a webcast to discuss these clinical results. ESMO Virtual Plenaries are monthly presentations of the latest, original scientific data, including “Phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need”.
The heavy selling pressure might have exhausted for Prima BioMed (IMMP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares).
SYDNEY, AUSTRALIA, June 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), through a subsidiary, to evaluate eftilagimod alfa (efti) in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in a pivotal Phase III trial.
Immutep Limited's lead molecule, eftilagimod, has shown signals of activity in lung cancer and has the potential to be a chemotherapy-free regimen with manageable toxicity. The company has received regulatory feedback on the design of a registrational trial for eftilagimod, indicating progress in its development. Immutep has a fairly strong financial position with $110 million AUD in cash and equivalents, providing them with several quarters of operational runway.
What type of business is Immutep Limited?
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
What sector is Immutep Limited in?
Immutep Limited is in the Healthcare sector
What industry is Immutep Limited in?
Immutep Limited is in the Biotechnology industry
What country is Immutep Limited from?
Immutep Limited is headquartered in Australia
When did Immutep Limited go public?
Immutep Limited initial public offering (IPO) was on 19 April 2012
What is Immutep Limited website?
https://www.immutep.com
Is Immutep Limited in the S&P 500?
No, Immutep Limited is not included in the S&P 500 index
Is Immutep Limited in the NASDAQ 100?
No, Immutep Limited is not included in the NASDAQ 100 index
Is Immutep Limited in the Dow Jones?
No, Immutep Limited is not included in the Dow Jones index
When was Immutep Limited the previous earnings report?
No data
When does Immutep Limited earnings report?
The next expected earnings date for Immutep Limited is 27 February 2025